Grifols pioneers high-tech analysis of plasma bank to detect early signs of Parkinson’s disease
Grifols submits Biologics License Application for its new fibrinogen solution to U.S. FDA
Grifols announces topline phase 3 data on long-term Albutein® (albumin [human] U.S.P.) therapy for decompensated cirrhosis with ascites
Our media relations team can be reached at:
(+34) 93 571 00 02
media@grifols.com.
Restricted to media inquiries only.
For general questions and requests, please contact corporatecomms@grifols.com.
Follow us on social media.
Seeking early biological signs of disease.
Newsroom
Access our latest press releases.
Media Center
Downloadable resources for media professionals.